首页> 外文期刊>Stroke: A Journal of Cerebral Circulation >Effects of admission hyperglycemia on stroke outcome in reperfused tissue plasminogen activator--treated patients.
【24h】

Effects of admission hyperglycemia on stroke outcome in reperfused tissue plasminogen activator--treated patients.

机译:入院高血糖对再灌注组织纤溶酶原激活剂治疗的患者中风预后的影响。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND AND PURPOSE: We sought to investigate the impact of hyperglycemia before reperfusion on long-term outcome in patients treated with intravenous tissue plasminogen activator (tPA). METHODS: Of 268 consecutive patients with a nonlacunar middle cerebral artery (MCA) stroke evaluated at <3 hours after onset, 73 (27.2%) received intravenous tPA. Serum glucose was determined at baseline before tPA administration. Hyperglycemia was defined as a glucose level >140 mg/dL. National Institutes of Health Stroke Scale (NIHSS) scores were obtained at baseline and 24 hours. Transcranial Doppler monitoring of recanalization and reocclusion was conducted during the first 24 hours. Total infarct volume was measured on CT at day 5 to 7. Modified Rankin Scale was used to assess outcome at 3 months. RESULTS: Median NIHSS score was 17. At baseline, 31 patients (42.5%) were hyperglycemic and 42 (57.5%) normoglycemic. Early reperfusion (<6 hours) occurred in 43 patients (58.9%). Admission blood glucose correlated negatively with the degree of neurological improvement at 24 hours in reperfused (r=-0.43; P=0.019) but not in nonreperfused (r=-0.20; P=0.21) tPA-treated patients. Increased age (P=0.014), history of diabetes mellitus (P=0.043), admission glucose >140 mg/dL (P=0.002), and early reocclusion (P=0.004) were factors associated with poor outcome among reperfused patients. A logistic regression modeling revealed that only admission glucose value >140 mg/dL (odds ratio, 8.4; 95% CI, 1.76 to 40.02; P=0.005) emerged as an independent predictor of poor outcome despite tPA-induced recanalization. In patients with 6-hour persistent MCA occlusion, baseline NIHSS score >15 points (P=0.011) and proximal MCA occlusion (P=0.039) were variables associated with poor outcome on univariate analysis. In a logistic regression model, only NIHSS score >15 points (odds ratio, 11.9; 95% CI, 1.48 to 97.1; P=0.032) remained as an independent predictor of poor outcome and functional dependence at 3 months in nonreperfused tPA-treated patients. CONCLUSIONS: Hyperglycemia before reperfusion may in part counterbalance the beneficial effect of early restoration of blood flow, which translates into a worse outcome in hyperglycemic patients despite tPA-induced recanalization.
机译:背景与目的:我们试图研究在用静脉组织纤溶酶原激活剂(tPA)治疗的患者中,再灌注前高血糖对长期预后的影响。方法:在发病后3小时内评估的268例连续的非腔中部大脑中风(MCA)患者中,有73例(27.2%)接受了静脉tPA治疗。在tPA给药前在基线测定血清葡萄糖。高血糖定义为葡萄糖水平> 140 mg / dL。美国国立卫生研究院卒中量表(NIHSS)评分是在基线和24小时获得的。在头24小时内进行经颅多普勒对再通和再闭塞的监测。在第5至7天在CT上测量总梗死体积。改良的Rankin量表用于评估3个月时的预后。结果:NIHSS评分中位数为17。在基线时,高血糖症患者31例(42.5%),正常血糖症患者42例(57.5%)。早期再灌注(<6小时)发生在43例患者中(58.9%)。在接受tPA治疗的患者中,再灌注(r = -0.43; P = 0.019)时,入院血糖与神经功能改善程度呈负相关(r = -0.43; P = 0.019),而未再灌注(r = -0.20; P = 0.21)与否。年龄增加(P = 0.014),糖尿病病史(P = 0.043),入院葡萄糖> 140 mg / dL(P = 0.002)和早期再入院(P = 0.004)是与再灌注患者预后不良相关的因素。 Logistic回归模型显示,尽管tPA引起的再通气,只有入院血糖值> 140 mg / dL(比值,8.4; 95%CI,1.76至40.02; P = 0.005)可作为不良预后的独立预测因子。在持续6小时的MCA闭塞的患者中,基线NIHSS得分> 15分(P = 0.011)和近端MCA闭塞(P = 0.039)是与单因素分析结果差相关的变量。在Logistic回归模型中,在未再灌注tPA治疗的患者中,只有NIHSS得分> 15分(优势比,11.9; 95%CI,1.48至97.1; P = 0.032)仍然是3个月结局和功能依赖性差的独立预测因子。结论:再灌注前的高血糖症可能会部分抵消早期恢复血流的有益作用,尽管tPA引起的再通气,这会使高血糖症患者的预后恶化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号